Cargando…

‘Targeting’ Improved Outcomes with Antibody-Drug Conjugates in Non-Small Cell Lung Cancer—An Updated Review

Antibody-Drug conjugates (ADCs) are a relatively new class of drugs with a promise to improve the outcomes in specific cancers. By delivering the cytotoxic agent to tumor cells expressing specific antigens, ADCs achieve a better therapeutic index and more potency. ADCs have been approved for several...

Descripción completa

Detalles Bibliográficos
Autores principales:	Verma, Saurav, Breadner, Daniel, Raphael, Jacques
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10137214/ https://www.ncbi.nlm.nih.gov/pubmed/37185443 http://dx.doi.org/10.3390/curroncol30040330

Ejemplares similares

The role of thoracic consolidative radiotherapy in the setting of immunotherapy in extensive stage small cell lung cancer
por: Verma, Saurav, et al.
Publicado: (2023)

A CD276-Targeted Antibody-Drug Conjugate to Treat Non-Small Lung Cancer (NSCLC)
por: Zhang, Jiashuai, et al.
Publicado: (2023)

One step too far in the right direction: The Society for Translational Medicine 2019 consensus on postoperative management of EGFR-mutant lung cancer
por: Breadner, Daniel, et al.
Publicado: (2020)

Antibody-Drug Conjugate Targeting c-Kit for the Treatment of Small Cell Lung Cancer
por: Kim, Kwang-Hyeok, et al.
Publicado: (2022)

NRXN1 as a novel potential target of antibody-drug conjugates for small cell lung cancer
por: Yotsumoto, Takuma, et al.
Publicado: (2020)

Quantitative pharmacology in antibody-drug conjugate development: armed antibodies or targeted small molecules?
por: Nessler, Ian, et al.
Publicado: (2018)

Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer
por: Feng, Liang, et al.
Publicado: (2016)

An antibody‐drug conjugate targeting a GSTA glycosite‐signature epitope of MUC1 expressed by non‐small cell lung cancer
por: Pan, Deng, et al.
Publicado: (2020)

Erratum to: Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer
por: Feng, Liang, et al.
Publicado: (2016)

Conjugates of Small Molecule Drugs with Antibodies and Other Proteins
por: Feng, Yang, et al.
Publicado: (2014)

Therapeutic index improvement of antibody-drug conjugates
por: Gerber, Hans-Peter, et al.
Publicado: (2023)

Unlocking New Horizons in Small-Cell Lung Cancer Treatment: The Onset of Antibody–Drug Conjugates
por: Belluomini, Lorenzo, et al.
Publicado: (2023)

Book Review: Antibody-Drug Conjugates: Fundamentals, Drug Development, and Clinical Outcomes to Target Cancer
por: Dhakal, Dipesh, et al.
Publicado: (2017)

Co-administered antibody improves penetration of antibody–dye conjugate into human cancers with implications for antibody–drug conjugates
por: Lu, Guolan, et al.
Publicado: (2020)

Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia
por: Liu, Delong, et al.
Publicado: (2019)

Targeting cancer with antibody-drug conjugates: Promises and challenges
por: Dean, Alexis Q., et al.
Publicado: (2021)

Improved targeting of an anti‐TAG‐72 antibody drug conjugate for the treatment of ovarian cancer
por: Minnix, Megan, et al.
Publicado: (2020)

Antibody-Oligonucleotide Conjugates: A Twist to Antibody-Drug Conjugates
por: Dugal-Tessier, Julien, et al.
Publicado: (2021)

Linked-In: Design and Efficacy of Antibody Drug Conjugates in Oncology
por: Feld, Jonathan, et al.
Publicado: (2013)

Novel Anti-FOLR1 Antibody–Drug Conjugate MORAb-202 in Breast Cancer and Non-Small Cell Lung Cancer Cells
por: Matsunaga, Yuki, et al.
Publicado: (2021)

An Efficient Conjugation Approach for Coupling Drugs to Native Antibodies via the Pt(II) Linker Lx for Improved Manufacturability of Antibody–Drug Conjugates
por: Merkul, Eugen, et al.
Publicado: (2021)

Computational selection of antibody-drug conjugate targets for breast cancer
por: Fauteux, François, et al.
Publicado: (2015)

Antibody drug conjugate: the “biological missile” for targeted cancer therapy
por: Fu, Zhiwen, et al.
Publicado: (2022)

Antibody-drug conjugates: the paradigm shifts in the targeted cancer therapy
por: Aggarwal, Devesh, et al.
Publicado: (2023)

Antibody-conjugated nanoparticles for target-specific drug delivery of chemotherapeutics
por: Kumari, Mamta, et al.
Publicado: (2023)

Advances in Targeted Therapy of Breast Cancer with Antibody-Drug Conjugate
por: Subhan, Md Abdus, et al.
Publicado: (2023)

ABBV-011, A Novel, Calicheamicin-Based Antibody–Drug Conjugate, Targets SEZ6 to Eradicate Small Cell Lung Cancer Tumors
por: Wiedemeyer, Wolf R., et al.
Publicado: (2022)

Introduction to Antibody-Drug Conjugates
por: Pettinato, Mark C.
Publicado: (2021)

ANTIBODY DRUG CONJUGATES (ADCS)
por: Terpos, E.
Publicado: (2023)

An update on antibody–drug conjugates in urothelial carcinoma: state of the art strategies and what comes next
por: D’Angelo, Alberto, et al.
Publicado: (2022)

Updated Views in Targeted Therapy in the Patient with Non-Small Cell Lung Cancer
por: Ortega, Miguel A., et al.
Publicado: (2023)

Antibody-drug conjugates in lung cancer: dawn of a new era?
por: Coleman, Niamh, et al.
Publicado: (2023)

Computational Construction of Antibody–Drug Conjugates Using Surface Lysines as the Antibody Conjugation Site and a Non-cleavable Linker
por: Filntisi, Arianna, et al.
Publicado: (2014)

Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non–Small Cell Lung Carcinoma
por: Camidge, D. Ross, et al.
Publicado: (2021)

Tumor-Targeted Drug Conjugates as an Emerging Novel Therapeutic Approach in Small Cell Lung Cancer (SCLC)
por: Deneka, Alexander Y., et al.
Publicado: (2019)

Improving the Stability of Maleimide–Thiol Conjugation for Drug Targeting
por: Lahnsteiner, Marianne, et al.
Publicado: (2020)

Targeting CD74 in B-cell non-Hodgkin lymphoma with the antibody-drug conjugate STRO-001
por: Li, Xiaofan, et al.
Publicado: (2023)

Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics
por: Kim, Eunhee G., et al.
Publicado: (2015)

Antibody–drug conjugates in solid tumors: a look into novel targets
por: Criscitiello, Carmen, et al.
Publicado: (2021)

Targeting CD56 with an antibody–drug conjugate in Merkel cell carcinoma
por: Leiendecker, L., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_m9f29a2b8rloabgsmf5p409174